AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19
1. Compared to placebo, intramuscular AZD7442 had a relative risk reduction of 76.7% for symptomatic incident coronavirus disease 2019 (COVID-19). ...
1. Compared to placebo, intramuscular AZD7442 had a relative risk reduction of 76.7% for symptomatic incident coronavirus disease 2019 (COVID-19). ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.